Immunotherapy has launched a new era for cancer treatment. Studies leading to the discovery of immune checkpoints and the effectiveness of their blockade have changed the way cancer patients are treated today. Over the last few decades, JEM has published landmark papers that have delineated the field of immunotherapy, some of which have contributed to the 2018 Nobel Prize in Physiology or Medicine for James Allison and Tasuku Honjo (http://jem.rupress.org/cc/2018-nobel-prize-collection). To underscore JEM's interest in this field and our commitment to publishing studies relevant to cancer treatment, we are expanding the JEM editorial board by adding two outstanding scientists who have made great contributions to understanding the cross-talk between cancer and immune cells and have led the way toward the development of new cancer therapies. We are extremely pleased to welcome Arlene Sharpe and Jedd Wolchok to the JEM board. Jedd D. Wolchok, MD, PhD, FASCO Jedd Wolchok is Chief of the Melanoma Service and holds the Lloyd J. Old Chair in Clinical Investigation at Memorial Sloan Kettering Cancer Center. He is also head of the Swim Across America Ludwig Collaborative Laboratory, Associate Director of the Ludwig Center for Cancer Immunotherapy, SU2C-ACS Lung Cancer Dream Team Co-leader, and Director of the Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center. Dr. Wolchok is a clinician-scientist exploring innovative immunotherapeutic strategies in laboratory models and a principal investigator in numerous pivotal clinical trials. He specializes in the treatment of melanoma. The focus of his translational research laboratory is to investigate innovative means to modulate the immune response to cancer as well as to better understand the mechanistic basis for sensitivity and resistance to currently available immunotherapies.
